CIRM Funded Clinical Trials

The CuRe Trial: Cellular Therapy for In Utero Myelomeningocele Repair and The CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele


Disease Area:
Developmental Disorders, Spina Bifida
Investigator:
Dr. Diana L. Farmer
Institution:
University of California, Davis
CIRM Grant:
CLIN2-12129 (Closed)
Award Value:
$8,946,474.00
Investigator:
Dr. Diana L. Farmer
Institution:
University of California, Davis
CIRM Grant:
CLIN2-15115 (Active)
Award Value:
$8,996,477.00
Trial Sponsor:
The Regents of the University of California, on behalf of its Davis campus
Trial Stage:
Phase 1|Phase 2
Trial Status:
Recruiting
Targeted Enrollment:
55
ClinicalTrials.gov ID:
NCT04652908

Details:

UC Davis is conducting a clinical trial for in utero repair of myelomeningocele (MMC), the most severe form of spina bifida.  MMC is a birth defect that occurs due to incomplete closure of the developing spinal cord, resulting in neurological damage to the exposed cord.  This damage leads to lifelong lower body paralysis, and bladder and bowel dysfunction.

The team will use placenta tissue to generate mesenchymal stem cells (MSCs).  The newly generated MSCs will be seeded onto an FDA approved dural graft and the product will be applied to the spinal cord while the infant is still developing in the womb.  The goal of this therapy is to help promote proper spinal cord formation and improve motor function, bladder function, and bowel function. 

Design:

This is a Phase I/IIA clinical trial. 

Goal:

To evaluate safety and preliminary efficacy. 

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website

ClinicalTrials.gov